Key Details
India has prohibited the manufacture, sale and distribution of 16 Fixed Dose Combinations (FDCs) under Section 26A of the Drugs and Cosmetics Act, 1940 after a scientific review concluded that the combinations lacked therapeutic justification and could pose risks to public health.
Key Area | Details |
|---|---|
Regulatory Action | Ban on 16 Fixed Dose Combinations (FDCs) |
Legal Basis | Section 26A, Drugs and Cosmetics Act, 1940 |
Scientific Review | DTAB-appointed Expert Committee |
Core Finding | Risks outweighed benefits; combinations lacked therapeutic rationale |
Product Categories Affected | Antibiotics, pain-relief medicines, antispasmodics, diabetes medicines and dermatological preparations |
Enforcement | Immediate prohibition on manufacture, sale and distribution |
Regulatory Objective | Promote rational drug use and strengthen medicine safety |
Summary
Strengthening Evidence-Based Pharmaceutical Regulation
The Ministry of Health and Family Welfare has prohibited 16 Fixed Dose Combinations (FDCs) after a scientific review by a DTAB Expert Committee found that the products lacked adequate therapeutic justification and posed potential risks to public health. The action has been taken under Section 26A of the Drugs and Cosmetics Act, 1940.
Removing Irrational Drug Combinations from the Market
The prohibited formulations span multiple categories, including certain antibiotic combinations, pain-relief medicines, antispasmodics, anti-diabetic formulations, and dermatological products. The review concluded that the combinations offered limited or no additional clinical benefit compared to the risks associated with their use.
The decision forms part of India’s continuing effort to promote rational drug use, improve medicine safety, and ensure that marketed products meet contemporary standards of efficacy and clinical evidence.
Supporting Patient Safety and Antimicrobial Stewardship
The ban is particularly significant for combinations involving antibiotics, where inappropriate use can contribute to antimicrobial resistance (AMR). By removing scientifically unsupported formulations, regulators aim to strengthen patient safety, improve prescribing practices, and reinforce confidence in India’s pharmaceutical regulatory framework.
What Is a Fixed Dose Combination (FDC)?
A Fixed Dose Combination (FDC) is a pharmaceutical product that combines two or more active ingredients in fixed proportions within a single dosage form. FDCs can improve treatment adherence and simplify therapy when scientifically justified. However, combinations that offer no additional therapeutic benefit or increase risks to patients are considered irrational and may be subject to regulatory action.
Policy Relevance
Greater patient safety through the removal of formulations whose risks outweigh demonstrated therapeutic benefits.
More rational use of antibiotics, supporting efforts to contain antimicrobial resistance and preserve the effectiveness of essential medicines.
Stronger evidence-based pharmaceutical regulation, with regulatory decisions increasingly guided by scientific review and clinical evidence.
Higher confidence in medicine quality standards, reinforcing India’s regulatory credibility as one of the world’s largest pharmaceutical producers.
A shift towards therapeutic value rather than product proliferation, encouraging manufacturers to focus on scientifically validated formulations.
Improved regulatory oversight of legacy medicines, ensuring older products remain subject to contemporary safety and efficacy assessments.
Relevant Question for Stakeholders: Should India establish a periodic review mechanism for all legacy Fixed Dose Combinations to ensure that medicines already on the market continue to meet current standards of safety, efficacy and therapeutic value?
Follow the Full Release Here: PIB Release on the Ban of 16 Fixed Dose Combinations